Other Compounds Sample Clauses
Other Compounds. In the event that Senomyx has not received payment under Section 7.1.1(b), then with respect to any Compound […***…], Firmenich will have up to […***…] from receipt of the data package under Section 3.1.2 for the applicable Compound to provide written notice to Senomyx that it has determined such Compound is Commercially Viable. In the event that Senomyx does not receive such written notice from Firmenich within the timeframe set forth above or in the event that Firmenich determines that such Compound is not Commercially Viable, then notwithstanding any other provision of this Agreement to the contrary, such Compound will thereafter not be considered a Selected Compound under the Agreement. In such event, Firmenich agrees to reimburse Senomyx pursuant to Section 3.3.3 for work performed until such date and any non cancelable costs. For the avoidance of doubt, costs incurred by Senomyx for such Compound will be included in the […***…] for purposes of Section 3.3.3.
Other Compounds. If Client controls or materially influences decisions regarding use of Services with respect to a molecule, compound or product described at the end of this Section 10(b) and is not restricted by a Partnering Agreement with respect to such molecule, compound or product, Client agrees during the Term to provide Cardinal Health with an exclusive right of negotiation for a period of sixty (60) days following delivery to Cardinal Health of a request for proposal and related background materials (“RFP”) to provide Services, provided that such Services are necessary and will be outsourced. The molecules, compounds or products that are subject of the foregoing rights are: (i) products resulting from Client’s other molecules or compounds in development, (ii) products resulting from molecules or compounds which Client purchases, licenses or otherwise assumes rights from a third party, or (iii) any pharmaceutical human therapeutic product that Client purchases, licenses or otherwise assumes commercialization rights from a third party.
Other Compounds. Other than the Compounds and the Series 2 Compounds, no Seller and no Affiliate of a Seller possesses any right, title, license, option or other interest in or to any compound or other molecule that was developed or arose through the use of the NYU Know-How or that [***]
Other Compounds. If, during the Research Term and the one year period thereafter, either of the parties identifies as a result of the Research a compound which appears to satisfy the definition of a Compound except that it does not produce a positive result in a Screening Assay, the parties agree to discuss in good faith additional amendments to the Collaboration Agreement as appropriate.
Other Compounds. In addition to finding leads from the ArQule Compound libraries and GTC Compound library, the Parties may license or purchase libraries of Other Compounds from Third Parties, as directed by the Research Committee and approved by the Steering Committee. In such event, the Parties will equally share expenses as provided in Section 4.1. Both GTC and ArQule will screen * Confidential Treatment has been requested for the marked portion.
Other Compounds. Hemispherian hereby agrees that the Company shall have an exclusive option to terminate the License Back with respect to any or all of the Other Compounds (the “Option”) during a period of 48 months commencing from the Asset Transfer Closing Date for those Other Compounds existing at such time, it being understood that such 48 month period will commence on an Other Compound-by-Other Compound basis as any new Other Compound arises and notice thereof is provided to the Company (the “Option Period”). At any time during the Option Period, the Company may provide written notice to Hemispherian that it is exercising the Option to terminate the License Back to any specific one of the Other Compounds (the “Selection Notice”). The Company may issue multiple Selection Notices throughout the Option Period to reflect the possibility that the License Back may be terminated with respect to certain compounds at different times. In the event that the Company issues a Selection Notice, (i) the License Back to the Other Compound specified therein shall terminate immediately; and (ii) the Company shall pay to Hemispherian the actual documented research and development costs specifically related to the selected Other Compound(s) in respect of which the License Back has been terminated incurred by Hemispherian (as shown by payment records) plus [***]%. Any of the Other Compounds which are not selected as aforesaid during the Option Period shall be released from the Option and Hemispherian shall have the right to continue to research, develop and commercialize such compounds, subject to the ROFR arrangement set out in Appendix A.
Other Compounds. During the Term, Abbott shall also have the right of first negotiation to exclusively license compounds ***.
Other Compounds